Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15:21:100571.
doi: 10.1016/j.jvacx.2024.100571. eCollection 2024 Dec.

Pulmonary embolism after SARS-CoV-2 vaccination

Björn Zethelius  1   2 , Sofia Attelind  1   3 , Gabriel Westman  1   4 , Rickard Ljung  1   5 , Anders Sundström  1   6
Affiliations

Pulmonary embolism after SARS-CoV-2 vaccination

Björn Zethelius et al. Vaccine X. .

Abstract

Background: During the COVID-19 vaccination campaign in Sweden, pulmonary embolism (PE) was a frequently reported suspected serious adverse drug reaction. The aim was to estimate risk of PE following vaccination for COVID-19 in the Swedish population aged 18 to 84 years.

Methods: Population-based cohort study using the CoVacSafe-SE established platform including national registers. PE-case definition: Individuals discharged from inpatient-care or visiting specialized outpatient-care with a main diagnosis of PE occurring between 27-Dec-2020 and 31-Dec-2022 without simultaneous diagnosis of COVID-19 infection. Time-to-event analysis was performed using multi-variable Cox' proportional hazard's models. Hazard Ratios (HR) adjusted for age, sex and co-morbidities were modelled.The vaccines were BNT162b2/Comirnaty®, mRNA1273/Spikevax® and ChAdOx1 nCoV-19/Vaxzevria® without regard to variants. Doses number one to five were studied.

Results: Eighty percent of the study-population (≈6.1 million people) received at least two doses of COVID-19 vaccine. A total of 12,456 cases of PE were identified. Twenty-eight days after vaccinations we observed 99 cases after 701,455 1st doses of ChAdOx1 nCoV-19, HRadj, 1.29 (95%-CI, 1.05-1.59). Corresponding for BNT162b2 was 361 cases after 4,708,284 1st doses of BNT162b2 HRadj of 1.19 (95%-CI, 1.06-1.34) driven by age group 65-84; HR adj, 1.24 (95%-CI, 1.07-1.44). No increased risks were observed for mRNA1273.

Conclusion: In this nation-wide study, no strong associations were found between COVID-19 vaccinations and pulmonary embolism. Small increases in relative risk for the earliest doses of vaccines may be associated with prioritizing the frailest groups of people in the vaccination campaign, thus selection bias or unmeasured residual confounding is possible.

Keywords: Booster vaccinations; COVID-19 vaccines; Primary vaccinations; Public health; Pulmonary embolism; Regulatory science; Vaccine safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Number of pulmonary emboli cases (bars) during the study period per 5-year intervals for women and men from 18 to 84 years of age and corresponding incidence per 10,000 person-years (dotted lines).
Fig. 2
Fig. 2
Hazard Ratios with 95 % confidence intervals for the outcome pulmonary emboli in 13 different age categories with 50–54 year of age as the reference for men (M; blue dots) and women (F; red dots). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3
Fig. 3
A-B. Forrest plot showing hazard ratios with 95 %-confidence intervals for the outcome pulmonary embolism at different risk windows up to 180 days, adjusted for sex and age in upper panel A and full adjustments in lower panel B for BNT 162b2 vaccine (BNT).
Fig. 4
Fig. 4
A-B. Forrest plot showing hazard ratios with 95 %-confidence intervals for the outcome pulmonary embolism at different risk windows up to 180 days, adjusted for sex and age in upper panel A and full adjustments in lower panel B for mRNA-1273 vaccine (MOD).
Fig. 5
Fig. 5
A-B. Forrest plot showing hazard ratios with 95 %-confidence intervals for the outcome pulmonary embolism at different risk windows up to 180 days, adjusted for sex and age in upper panel A and full adjustments in lower panel B for ChAdOx1 nCoV-19 vaccine (AZ).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Katsoularis I., Fonseca-Rodríguez O., Farrington P., Jerndal H., Lundevaller E.H., Sund M., et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr;6(377):e069590. PMID: 35387772. - PMC - PubMed
    1. Safiriyu I., Fatuyi M., Mehta A., Naser A., Alexander E., Vovan H., Shamaki G.R., Bob-Manuel T. Impact of COVID-19 Infection on the Clinical Outcomes of Pulmonary Embolism Hospitalizations : A Nationwide Analysis. Curr Probl Cardiol. 2023;48(7):101669. doi: 10.1016/j.cpcardiol.2023.101669. Epub 2023 Feb 23. PMID: 36841316. - DOI - PMC - PubMed
    1. Law N., Chan J., Kelly C., Auffermann W.F., Dunn D.P. Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta Omicron variants and vaccines. Emerg Radiol. 2022 Aug;29(4):625–629. doi: 10.1007/s10140-022-02039-z. Epub 2022 Apr 21 PMID: 3544600. - DOI - PMC - PubMed
    1. Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar;28(3):583–590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7 PMID: 35132265. - DOI - PMC - PubMed
    1. Kalinke U., Barouch D.H., Rizzi R., Lagkadinou E., Türeci Ö., Pather S., et al. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022 May;21(5):609–619. doi: 10.1080/14760584.2022.2042257. Epub 2022 Mar 14 PMID: 35157542. - DOI - PMC - PubMed

LinkOut - more resources